Global Market For Enzyme Inhibitors

June 15, 2012

Wellesley, Mass. – According to a new technical market research report, GLOBAL MARKETS FOR ENZYME INHIBITORS (BIO057B) from BCC Research (www.bccresearch.com), the global market for enzyme inhibitors was worth nearly $104.6 billion in 2011. This figure is projected to reach $127.4 billion in 2016, a five-year compound annual growth rate (CAGR) of 4%.

The enzyme inhibitors market can be broken down into three regions: the United States, Europe, and emerging markets.

The United States accounted for nearly $45 billion in 2011 and should reach nearly $47.5 billion in 2016, a CAGR of 1.1%.

Europe totaled $32.4 billion in 2011 and should reach nearly $38.7 billion in 2016, a CAGR of 3.6%.

The region made up of emerging markets accounted for $27.2 billion in 2011 and should reach nearly $41.3 billion in 2016, a CAGR of 8.7%.

Enzyme inhibitors, a therapeutic category indicated for the treatment of various life-threatening chronic diseases, is inevitably an important therapeutic category in the pharmaceutical industry.  An increasing aging population, pandemic threats and sedentary lifestyles are increasing the incidence of disease throughout the world. For many years, research-based companies have been making significant contributions to tackle world health problems by developing innovative life-saving drugs, including target-specific drugs such as kinase inhibitors and reverse transcriptase inhibitors.

At present, Roche-Genentech, AstraZeneca, Pfizer, Novartis, Merck and Takeda are dominating the market. Other companies also contribute to the market share of enzyme inhibitors in the pharmaceutical and biotechnology industries.

This report deals with the various categories of therapeutic enzyme inhibitors, where the market for enzyme inhibitors is analyzed by class and by disease type. Categories of enzyme inhibitors include proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors.

In addition to BIO057B, BCC also has published BIO105A, BIO106A, and BIO107A. These reports cover enzyme inhibitors with focuses, respectively, on the United States, Europe, and Emerging Markets regions. 

To Contact us, click here  

Global Markets for Enzyme Inhibitors( BIO057B )
Publish Date: Jun 2012    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.